Symbio Pharmaceuticals Faces Steep Decline in H1 FY2024

Symbio Pharmaceuticals Limited (JP:4582) has released an update.

Symbio Pharmaceuticals Limited reported a significant decline in financial performance for the first half of FY 2024, with net sales decreasing by 59.6% and a notable net loss attributable to owners of the parent. The company’s total assets have also seen a decrease from the previous fiscal year end. Despite these results, equity ratio remains stable at 85.0%, and no dividends have been paid or forecasted for FY 2024.

For further insights into JP:4582 stock, check out TipRanks’ Stock Analysis page.